JN Medsys

【AEA 2020 Alumni】
JN Medsys is a Singapore biomedical company dedicated to providing super resolution genomic tools for precise and personalized diagnostics. Founded in 2010, our vision is to improve lives through advanced diagnostics in healthcare. We have been working relentlessly over the years to create cutting-edge genomic tools, comprising instruments and kits, that provide better sensitivity and accuracy for nucleic acids analysis. Through these advanced diagnostics, we hope to generate actionable insights to improve the outcomes of cancer and to eradicate infectious diseases. More recently, we have developed an end-to-end solution for Covid-19 testing. Our test is able to provide accurate, fast, and high capacity Covid-19 testing, even for countries which have limited resources.

CEO and Founder

Nominated by

Business Dev & PR
JETRO Singapore
JN Medsys’ vision to improve lives through advanced diagnostics is continually met through their cutting-edge genomic tools providing better sensitivity and accuracy in their results. The company adapted their technology quickly and accurately to develop a new testing solution for COVID-19, which is already being shipped in more than 10 countries. This will allow the healthcare systems that use their products/solution to function more efficiently, which can allow for the institutions to become more productive and channel their resources better.

Their determination is shown through the companies resolve as they continually fine-tune their solution so that they continue to stay relevant and expand their network. From cancer diagnostics to infectious diseases, now specifically for COVID-19.

In roughly 10 years, JN Medsys have managed to form distribution networks across the world.

With their experience, networks and most importantly, their technology, JN Medsys has the ability to collaborate with the Japanese players to develop more solutions for the healthcare industry.